<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352413</url>
  </required_header>
  <id_info>
    <org_study_id>HE071-CSP-010</org_study_id>
    <nct_id>NCT04352413</nct_id>
  </id_info>
  <brief_title>A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy</brief_title>
  <official_title>An Open-label, Multi-center, Phase 2 Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection (PLM60) in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, multicenter phase II clinical study for PLM60. The primary aim of the study&#xD;
      is to observe the initial efficacy of PLM60 in treatment of small cell lung cancer. The&#xD;
      secondary aim is to explore the safety and PK characteristics of PLM60&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate ORR in SCLC subjects treated with PLM60</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate DoR in SCLC subjects treated with PLM60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate DCR in SCLC subjects treated with PLM60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate PFS in SCLC subjects treated with PLM60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate OS in SCLC subjects treated with PLM60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate the safety profiles in SCLC subjects treated with PLM60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>To evaluate the safety profiles in SCLC subjects treated with PLM60</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A: PLM60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/m2, 4 weeks/cycle, administered on day 1 of each cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: PLM60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg/m2, 3 weeks/cycle, administered on day 1 of each cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLM60</intervention_name>
    <description>Administration: Intravenous infusion</description>
    <arm_group_label>Cohort A: PLM60</arm_group_label>
    <arm_group_label>Cohort B: PLM60</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of SCLC;&#xD;
&#xD;
          2. Must have recurrence or progression after platinum-based first-line chemotherapy or&#xD;
             chemoradiation therapy for the treatment of SCLC;&#xD;
&#xD;
          3. ECOG performance status 0~2;&#xD;
&#xD;
          4. Measurable lesion according to RECIST v1.1;&#xD;
&#xD;
          5. Life expectancy â‰¥ 12 weeks;&#xD;
&#xD;
          6. Adequate organ function;&#xD;
&#xD;
          7. Signed informed consent from the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Radical surgical treatment for primary small cell lung cancer;&#xD;
&#xD;
          2. Any anti-tumor treatment received within 4 weeks before the first use of the study&#xD;
             drug;&#xD;
&#xD;
          3. Untreated or symptomatic central nervous system (CNS) metastases;&#xD;
&#xD;
          4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated&#xD;
             drainage;&#xD;
&#xD;
          5. History of serious systemic diseases;&#xD;
&#xD;
          6. History of serious autoimmune diseases;&#xD;
&#xD;
          7. Those receiving treatment of adriamycin or other anthracyclines previously, with the&#xD;
             total cumulative adriamycin (or adriamycin-equivalent) dose of &gt;360 mg/m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun Lou</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medicine, CSPC Clinical Development Division</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kun Lou</last_name>
    <phone>0311-67808817</phone>
    <email>loukun@mail.ecspc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xuefang Xia</last_name>
    <phone>010-63930702</phone>
    <email>xiaxuefang@mail.ecspc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Zhou</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

